Posted 1/19/2024, 5:19:27 PM
AI-Designed Compound Shows Promise for Treating Breast and Gynecological Cancers
- Insilico Medicine used AI to identify MYT1 as a promising target for treating breast and gynecological cancers
- Insilico's Chemistry42 platform designed novel, selective MYT1 inhibitor compounds from scratch
- Lead compound 21 shows good activity, selectivity over Wee1, and antitumor efficacy in preclinical studies
- Study published in Journal of Medicinal Chemistry demonstrates innovative AI-driven target ID and drug discovery
- Selective MYT1 inhibitors could enable a safer, more effective treatment approach for these cancers